Abiopharma

🔍 Novara Mark David (Executive)

Company: TANDEM DIABETES CARE INC (TNDM)

Report Date: 2026-03-16

Detailed Transactions and Holdings:

• Acquired 7,414 shares of Common Stock (Direct)
  Date: 2026-03-16 | Code: M | equity_swap_involved: 0 | shares_owned_after: 43,383.00 | transaction_form_type: 4
• Sold 5,540 shares of Common Stock at $21.59 per share (Direct)
  Date: 2026-03-16 | Code: F | equity_swap_involved: 0 | shares_owned_after: 37,843.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 187 shares of Common Stock at $23.05 per share (Direct)
  Date: 2026-03-17 | Code: S | equity_swap_involved: 0 | shares_owned_after: 37,656.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 7,414 shares of Restricted Stock Unit (Derivative)
  Date: 2026-03-16 | Code: M | equity_swap_involved: 0 | shares_owned_after: 22,244.00 | transaction_form_type: 4 | Footnotes: F3, F4, F5, F5

Footnotes:

• F1: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.
• F2: The shares were sold, pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 4, 2025.
• F3: Awarded on December 15, 2023 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).
• F4: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.
• F5: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 12/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.